STERIS plc — Form 8-K
Filed August 5, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 42/100
What the filing says
STERIS reported Q1 FY2027 (ended June 30, 2026) revenue of $1.492B (+7% YoY; 6% constant-currency organic). Adjusted diluted EPS increased to $2.59 from $2.34. The company announced a targeted restructuring related to consolidating formulated chemistries manufacturing to a new Center of Excellence in North Carolina, with expected pre-tax charges of $55M–$70M ($40M–$50M cash, $15M–$20M non-cash) over completion by fiscal 2030. Full-year FY2027 guidance unchanged: 7–8% revenue growth, adjusted EPS $11.10–$11.30; capex raised from $375M to $450M; free cash flow lowered from $850M to $800M.
Why this rating
Solid organic growth and restructuring investment are routine; $62.5M midpoint charge (0.26% of $24.2B market cap) and $75M capex boost (0.31%) are modest relative to company size.
See more from August 5, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.